Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06085937 · ClinicalTrials.gov registry record · Phase 1
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
A Phase 1 study of Depression and Suicide, sponsored by Lindsay Maguire, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT06085937 is a Phase 1 study of Depression and Suicide that is actively recruiting participants, run by Lindsay Maguire, MD. The registered enrollment target is 50 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06085937, a Phase 1 study of Depression and Suicide, is actively recruiting participants, sponsored by Lindsay Maguire, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
Conditions Studied
Interventions
- DRUG Ketamine
Study Locations (2)
Kansas
- University of Kansas Strawberry Hill Campus - Kansas City
- University of Kansas Medical Center Emergency Department - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06085937
The ClinicalTrials.gov registry entry for NCT06085937 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower). The listed sponsor is Lindsay Maguire, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.
NCT06085937 reports 2 study locations spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT06085937 about?
NCT06085937 is a clinical study titled "Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department". There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who pr...
What is the current status of trial NCT06085937?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-05-01. Estimated completion is 2026-04.
What conditions does trial NCT06085937 study?
This clinical trial studies the following conditions: Depression, Suicide, Suicidal Ideation.
What interventions are being tested in trial NCT06085937?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT06085937?
This trial is sponsored by Lindsay Maguire, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06085937 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.